Phio Pharmaceuticals Reports Positive Results in Skin Cancer Trial
Phio Pharmaceuticals reports positive pathology results from its Phase 1b trial of the cancer therapeutic INTASYL PH-762, showing high tumor clearance rates and a favorable safety profile, indicating potential as a non-surgical treatment for skin cancers.